A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies

Trial Profile

A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Oct 2017

At a glance

  • Drugs INCB 54329 (Primary)
  • Indications Acute myeloid leukaemia; Leukaemia; Lymphoma; Multiple myeloma; Myelodysplastic syndromes; Myelofibrosis; Solid tumours
  • Focus Adverse reactions
  • Sponsors Incyte Corporation
  • Most Recent Events

    • 01 Aug 2017 According to an Incyte Corporation media release, data expected to be presented at medical meetings in the second half of 2017.
    • 09 May 2017 Status changed from recruiting to active, no longer recruiting.
    • 10 Apr 2017 Planned number of patients changed from 155 to 340.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top